MY156913A - Oral administration of peripherally-acting opioid antagonists - Google Patents

Oral administration of peripherally-acting opioid antagonists

Info

Publication number
MY156913A
MY156913A MYPI2010005212A MYPI20105212A MY156913A MY 156913 A MY156913 A MY 156913A MY PI2010005212 A MYPI2010005212 A MY PI2010005212A MY PI20105212 A MYPI20105212 A MY PI20105212A MY 156913 A MY156913 A MY 156913A
Authority
MY
Malaysia
Prior art keywords
peripherally
oral administration
opioid antagonists
acting opioid
acting
Prior art date
Application number
MYPI2010005212A
Other languages
English (en)
Inventor
Kevin J Brodbeck
Alan R Kugler
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MY156913A publication Critical patent/MY156913A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2010005212A 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists MY156913A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07

Publications (1)

Publication Number Publication Date
MY156913A true MY156913A (en) 2016-04-15

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010005212A MY156913A (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US8524276B2 (en) * 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
MX2013003587A (es) 2010-09-30 2013-05-31 Nektar Therapeutics Conjugados de naloxol-polietilenglicol cristalinos.
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN106470999B (zh) 2014-04-28 2018-11-13 奥佛麦德公司 叔丁啡二聚体及其在治疗肠胃失调中的应用
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CZ299726B6 (cs) * 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN101466381B (zh) * 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药

Also Published As

Publication number Publication date
IL208794A0 (en) 2010-12-30
AU2009244805A1 (en) 2009-11-12
KR20110004425A (ko) 2011-01-13
EP2300009A1 (en) 2011-03-30
JP2011519930A (ja) 2011-07-14
NZ589733A (en) 2012-07-27
ZA201007531B (en) 2012-03-28
BRPI0912219A2 (pt) 2015-10-06
CA2723685A1 (en) 2009-11-12
CN102014907A (zh) 2011-04-13
MX2010011727A (es) 2010-11-30
WO2009137086A1 (en) 2009-11-12
CA2723685C (en) 2016-09-27
EA201001643A1 (ru) 2011-06-30
AU2009244805B2 (en) 2013-01-10
US20110160239A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MY156913A (en) Oral administration of peripherally-acting opioid antagonists
GB0807605D0 (en) Lipid composition
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
AU2011328497A8 (en) Dosing regimen for sedation with CNS 7056 (remimazolam)
ZA201100615B (en) Appetising medicament for oral administration in solid form
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
IL216159A (en) Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EA201490304A1 (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
MY149731A (en) Compounds
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TW200744568A (en) Epinephrine dosing regimens
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX339470B (es) Formulacion que contiene nicotina.
NZ592049A (en) Compositions and methods for the treatment of bowel diseases with granulated mesalamine
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
EP2114418A4 (en) ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
CY1120920T1 (el) Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο
MX2014006824A (es) Derivados de espirotienopiran-piperidina como antagonistas del receptor orl-1 para su uso en el tratamiento de dependencia y abuso de alcohol.